<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525782</url>
  </required_header>
  <id_info>
    <org_study_id>2018-006</org_study_id>
    <nct_id>NCT03525782</nct_id>
  </id_info>
  <brief_title>Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC</brief_title>
  <official_title>A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Anjie Biomedical Technology Co;LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Technology, Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Guangdong Pharmaceutical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1
      knockout engineered T cells for patients with advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a combined phase 1 and 2 clinical study. The study is to assess the safety and
      efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients
      with advanced non-small cell lung cancer. The treatment outcomes will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>Safety and tolerability of dose of CART-cells and PD-1 Knockout T cells will be assessed using CTCAE v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Will be assessed according to the revised RECIST guideline v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival - OS</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Measure the time from enrollment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - PFS</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time from enrollment to date of first documented progression or date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median CAR-T cell persistence</measure>
    <time_frame>4 years</time_frame>
    <description>Will be measured by quantitative RT-PCR</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Neoplasm Malignant</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAR-T combining PD-1 knockout</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1 knockout</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-1 mAb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T Cells</intervention_name>
    <description>Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.</description>
    <arm_group_label>CAR-T</arm_group_label>
    <arm_group_label>CAR-T combining PD-1 knockout</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CAR-T combining PD-1 Knockout</intervention_name>
    <description>Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients</description>
    <arm_group_label>CAR-T combining PD-1 knockout</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 knockout</intervention_name>
    <description>Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients</description>
    <arm_group_label>CAR-T combining PD-1 knockout</arm_group_label>
    <arm_group_label>PD-1 knockout</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 mAb</intervention_name>
    <description>Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1</description>
    <arm_group_label>PD-1 mAb</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham control</intervention_name>
    <description>Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MUC1 is expressed in malignancy tissues by immuno-histochemical (IHC).

          -  Eastern cooperative oncology group (ECOG) performance status of 0-1 or karnofsky
             performance status (KPS) score is higher than 60.

          -  Patients have a life expectancy &gt; 12 weeks.

          -  Adequate venous access for apheresis or venous sampling, and no other
             contraindications for leukapheresis.

          -  Negative pregnancy test for females of child-bearing potentials.

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥
             9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and
             amylase &lt; 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate
             aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal,
             serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to
             registration.

          -  Signed informed consent form.

        Exclusion Criteria:

          -  Number of T cells is less than 10% or the amplification of the T cells via artificial
             antigen presenting cell (aAPC) stimulation is less than 5 times.

          -  Patients with symptomatic central nervous system (CNS) involvement.

          -  Pregnant or nursing women.

          -  Known HIV infection.

          -  Serious illness or medical condition which would not permit the patient to be managed
             according to the protocol, including active uncontrolled infection, major
             cardiovascular, coagulation disorders, respiratory or immune system, myocardial
             infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or
             psychiatric or emotional disorders.

          -  History of severe immediate hypersensitivity to any of the agents including
             cyclophosphamide, fludarabine, or aldesleukin.

          -  Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not
             exclusionary.

          -  Previously treatment with any gene therapy products.

          -  The existence of unstable or active ulcers or gastrointestinal bleeding. Patients with
             portal vein vascular invasion or extrahepatic, are excluded from this study.

          -  Patients with a history of organ transplantation or are waiting for organ
             transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guobiao Huang</last_name>
      <phone>86-20-39352064</phone>
      <email>153706227@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Professor Size Chen</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Size Chen, MD,PhD</last_name>
      <phone>+8613720956393</phone>
      <email>13720956393@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhizhou Huang, MSc</last_name>
      <phone>+8613268258980</phone>
      <email>hzhizhou@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yiguang Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Size Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micheal Yin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Professor Size Chen</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Size Chen, MD,PhD</last_name>
      <phone>+8613720956393</phone>
      <email>13720956393@139.com</email>
    </contact>
    <investigator>
      <last_name>Yiguang Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micheal Yin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangdong Pharmaceutical University</investigator_affiliation>
    <investigator_full_name>Size Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CAR-T cell therapy</keyword>
  <keyword>MUC+</keyword>
  <keyword>PD-1 Knockout</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

